quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

ZenaTech anuncia su 21ª adquisición, ampliando su red nacional de Drone como Servicio y su presencia en el noroeste del Pacífico para atender a empresas y gobiernos

View original at globenewswire.com
ZenaTech anuncia su 21ª adquisición, ampliando su red nacional de Drone como Servicio y su presencia en el noroeste del Pacífico para atender a empresas y gobiernos VANCOUVER, British Columbia, April 10, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ZenaTech is bringing field efficiency as well as high-value data and insights that help businesses and governments make faster and smarter decisions at scale

    60% confidence
  • DaaS goes beyond flying drones by providing an AI-driven autonomy platform that converts aerial operations into continuous, actionable intelligence while automating labor-intensive manual tasks

    60% confidence
  • Strengthening operations in the Pacific Northwest positions ZenaTech at the intersection of forestry and environmental monitoring, critical energy infrastructure, and port and logistics surveillance, which is precisely where Drone as a Service offers the greatest value for mission-critical operations

    60% confidence

Data points we hold from this source

ZenaTech, Inc. · acquisition count21 acquisitions
ZenaTech, Inc. · daas location count24 locations
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com